Cencora reports Q3 adjusted EPS $3.34, consensus $3.22

Reports Q3 revenue $74.2B, consensus $73.48B. “We are pleased to raise our fiscal 2024 guidance following Cencora’s strong third quarter results, as our purpose-driven team members exhibited another quarter of solid execution against our pharmaceutical-centric strategy,” said Steven Collis, Chairman, President & Chief Executive Officer of Cencora. “Throughout my time as Cencora’s CEO, our strategic positioning at the center of healthcare has allowed our company to capitalize on market growth and innovation while enhancing our capabilities to help our customers navigate the complexity of the ever-changing healthcare environment,” Collis continued. “As I move into my new role as Executive Chairman of the Board on October 1st, I am incredibly proud of the growth and evolution of our enterprise, and as COO Bob Mauch concurrently transitions into his new role of CEO, I am confident that Cencora will continue to drive long-term value creation for its partners and stakeholders.”